Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen beats Street

AMGN reported 3Q07 adjusted diluted EPS of $1.08, beating by $0.05 the Street consensus of $1.03 and up 4% from $1.04 in 3Q06. Revenues, however, were flat at $3.6 billion in both quarters, while sales edged up 1% to $3.52 billion in

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers